U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA failed to inspect a Chinese API manufacturer that may be linked to a recent heparin safety scare because the wrong Chinese firm was entered into an agency database, a compliance official said Feb. 18
You may also be interested in...
Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move
TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill
Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move
TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill
U.S. FDA Move “Beyond Our Borders” Begins With China
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
Need a specific report? 1000+ reports available
Buy Reports